Concepedia

Karl Miranda

KM

8

Publications

338

Citations

8

H-Index

2005

Active since

Affiliations

Novartis (Switzerland)(Current)

Brigham Young University

Novartis (United States)

Novartis Institutes for BioMedical Research

Rega Institute for Medical Research

Karl Miranda is an author at Novartis (Switzerland) specializing in drug discovery, pharmacology, and medicine.

Top concepts

Publications per year

2005–2018

8

Publications

8

A novel kinase inhibitor establishes a predominant role for protein kinase D as a cardiac class IIa histone deacetylase kinase

Lauren G. Monovich, Richard B. Vega, Erik L. Meredith et al. · FEBS Letters · 2009 · 58 citations

Identification of Orally Available Naphthyridine Protein Kinase D Inhibitors

Erik L. Meredith, Ophelia Ardayfio, Kimberly Beattie et al. · Journal of Medicinal Chemistry · 2010 · 53 citations · Full text

, , +11

Discovery and in Vivo Evaluation of Potent Dual CYP11B2 (Aldosterone Synthase) and CYP11B1 Inhibitors

Erik L. Meredith, Gary M. Ksander, Lauren G. Monovich et al. · ACS Medicinal Chemistry Letters · 2013 · 46 citations · Full text

Synthesis and Biological Evaluation of 6-(Alkyn-1-yl)furo[2,3<i>-d</i>]pyrimidin-2(3<i>H</i>)-one Base and Nucleoside Derivatives

Morris J. Robins, Karl Miranda, Vivek K. Rajwanshi et al. · Journal of Medicinal Chemistry · 2005 · 46 citations

Identification of Potent and Selective Amidobipyridyl Inhibitors of Protein Kinase D

Erik L. Meredith, Kimberly Beattie, Robin Burgis et al. · Journal of Medicinal Chemistry · 2010 · 41 citations · Full text

, , +19

Rows per page

1–5 of 8